Anatara Lifesciences Ltd has released a press release.
Appendix 4C & Q4 FY23 Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Anatara Lifesciences Ltd on 6ix
Story so far
Earlier from Anatara Lifesciences
- Anatara Update on GaRP Irritable Bowel Syndrome Trial
- Appendix 4C & Q3 FY23 Activities Report
- Anatara Company Update
- Half Yearly Report and Accounts
- Placement of Shortfall from Entitlement Offer
Later from Anatara Lifesciences
- $923,235 in R&D tax incentive received
- Appendix 4E & Audited Financial Statements 30 June 2023
- IBS clinical trial Stage 1 patients finalised
- ANR announces Positive Results from Stage 1 of IBS trial
- Anatara IBS trial positive secondary endpoint data analysis
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences